enGene Holdings Inc. (NASDAQ:ENGN) Receives $22.86 Average Target Price from Brokerages

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have been assigned a consensus rating of “Moderate Buy” from the ten research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $22.8571.

Several equities research analysts recently commented on ENGN shares. Citigroup reiterated a “market outperform” rating on shares of enGene in a report on Monday, January 5th. Jefferies Financial Group initiated coverage on shares of enGene in a research note on Friday, January 30th. They set a “buy” rating and a $28.00 target price on the stock. Oppenheimer dropped their price target on shares of enGene from $33.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, March 11th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of enGene in a research note on Monday, March 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of enGene in a report on Friday, January 9th.

Institutional Investors Weigh In On enGene

A number of hedge funds have recently added to or reduced their stakes in ENGN. XTX Topco Ltd bought a new position in shares of enGene during the 4th quarter valued at $216,000. Vestal Point Capital LP grew its holdings in shares of enGene by 185.1% in the fourth quarter. Vestal Point Capital LP now owns 1,055,000 shares of the company’s stock worth $9,527,000 after acquiring an additional 685,000 shares during the period. Virtus Investment Advisers LLC bought a new stake in shares of enGene in the fourth quarter worth $284,000. Quadrature Capital Ltd purchased a new stake in enGene during the fourth quarter valued at $439,000. Finally, Perceptive Advisors LLC increased its position in enGene by 179.8% during the fourth quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock valued at $52,998,000 after acquiring an additional 3,771,840 shares during the last quarter. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

enGene Stock Performance

ENGN stock opened at $6.18 on Thursday. The stock’s 50 day simple moving average is $9.00 and its 200 day simple moving average is $8.31. The company has a current ratio of 11.75, a quick ratio of 11.75 and a debt-to-equity ratio of 0.09. enGene has a 12-month low of $2.65 and a 12-month high of $12.25. The stock has a market capitalization of $414.00 million, a PE ratio of -2.75 and a beta of -0.29.

enGene (NASDAQ:ENGN) last posted its earnings results on Monday, March 9th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.11. As a group, research analysts forecast that enGene will post -1.56 earnings per share for the current fiscal year.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.